PROFILO GENERALE DELLA FLUVOXAMINA

D. De Maio; A. Bertolino; M. Casacchia; G. Ceccarelli; U. Ecari; C. Giove; A. Marino; A. A. Rizzoli; F. Savoldi

PROFILO GENERALE DELLA FLUVOXAMINA

Translated title of the contribution: General profile of fluvoxamine

D. De Maio, A. Bertolino, M. Casacchia, G. Ceccarelli, U. Ecari, C. Giove, A. Marino, A. A. Rizzoli, F. Savoldi

IRCCS Casa Sollievo della Sofferenza

Research output: Contribution to journal › Article › peer-review

Abstract

A brief report on the Consensus Conference on Fluvoxamina held in Moasca (Asti) in September 1990 in presented which describes a general profile of the drug. Fluvoxamine (a Selective Serotonin Reuptake Inhibitor) main features are reported, which include its clinically proven efficacy as and antidepressant agent, with a particularly strong efficacy on suicidal thoughts, and a particularly favourable safety profile (i.e. virtual absence of anticholinergicc activity, lack of cardiotoxicity. The clinically proven efficacy of fluvoxamine in the treatment of Anxiety Disorders (Panic attacks and Obsessive-Compulsive Disorder) is also reported. Besides these already established therapeutic indications, fluvoxamine can play a useful role in the treatment of other disorders (Eating disorders, Aggressive Behaviour Drug Use Disorder, etc.) biochemically characterized by a disordered central serotoninergic neurotransmission.

Translated title of the contribution	General profile of fluvoxamine
Original language	Italian
Pages (from-to)	626-650
Number of pages	25
Journal	Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali
Volume	115
Issue number	4
Publication status	Published - 1991

ASJC Scopus subject areas

Psychiatry and Mental health

Cite this

@article{67e7d63ff512494b9c063346fda5cfcb,

title = "PROFILO GENERALE DELLA FLUVOXAMINA",

abstract = "A brief report on the Consensus Conference on Fluvoxamina held in Moasca (Asti) in September 1990 in presented which describes a general profile of the drug. Fluvoxamine (a Selective Serotonin Reuptake Inhibitor) main features are reported, which include its clinically proven efficacy as and antidepressant agent, with a particularly strong efficacy on suicidal thoughts, and a particularly favourable safety profile (i.e. virtual absence of anticholinergicc activity, lack of cardiotoxicity. The clinically proven efficacy of fluvoxamine in the treatment of Anxiety Disorders (Panic attacks and Obsessive-Compulsive Disorder) is also reported. Besides these already established therapeutic indications, fluvoxamine can play a useful role in the treatment of other disorders (Eating disorders, Aggressive Behaviour Drug Use Disorder, etc.) biochemically characterized by a disordered central serotoninergic neurotransmission.",

author = "{De Maio}, D. and A. Bertolino and M. Casacchia and G. Ceccarelli and U. Ecari and C. Giove and A. Marino and Rizzoli, {A. A.} and F. Savoldi",

year = "1991",

language = "Italian",

volume = "115",

pages = "626--650",

journal = "Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali",

issn = "0035-7057",

number = "4",

}

TY - JOUR

T1 - PROFILO GENERALE DELLA FLUVOXAMINA

AU - De Maio, D.

AU - Bertolino, A.

AU - Casacchia, M.

AU - Ceccarelli, G.

AU - Ecari, U.

AU - Giove, C.

AU - Marino, A.

AU - Rizzoli, A. A.

AU - Savoldi, F.

PY - 1991

Y1 - 1991

N2 - A brief report on the Consensus Conference on Fluvoxamina held in Moasca (Asti) in September 1990 in presented which describes a general profile of the drug. Fluvoxamine (a Selective Serotonin Reuptake Inhibitor) main features are reported, which include its clinically proven efficacy as and antidepressant agent, with a particularly strong efficacy on suicidal thoughts, and a particularly favourable safety profile (i.e. virtual absence of anticholinergicc activity, lack of cardiotoxicity. The clinically proven efficacy of fluvoxamine in the treatment of Anxiety Disorders (Panic attacks and Obsessive-Compulsive Disorder) is also reported. Besides these already established therapeutic indications, fluvoxamine can play a useful role in the treatment of other disorders (Eating disorders, Aggressive Behaviour Drug Use Disorder, etc.) biochemically characterized by a disordered central serotoninergic neurotransmission.

AB - A brief report on the Consensus Conference on Fluvoxamina held in Moasca (Asti) in September 1990 in presented which describes a general profile of the drug. Fluvoxamine (a Selective Serotonin Reuptake Inhibitor) main features are reported, which include its clinically proven efficacy as and antidepressant agent, with a particularly strong efficacy on suicidal thoughts, and a particularly favourable safety profile (i.e. virtual absence of anticholinergicc activity, lack of cardiotoxicity. The clinically proven efficacy of fluvoxamine in the treatment of Anxiety Disorders (Panic attacks and Obsessive-Compulsive Disorder) is also reported. Besides these already established therapeutic indications, fluvoxamine can play a useful role in the treatment of other disorders (Eating disorders, Aggressive Behaviour Drug Use Disorder, etc.) biochemically characterized by a disordered central serotoninergic neurotransmission.

UR - http://www.scopus.com/inward/record.url?scp=0025999996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025999996&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0025999996

VL - 115

SP - 626

EP - 650

JO - Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali

JF - Rivista Sperimentale di Freniatria e Medicina Legale delle Alienazioni Mentali

SN - 0035-7057

IS - 4

ER -

PROFILO GENERALE DELLA FLUVOXAMINA

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this